A previous study by Karhemo et al., reported that PTGFRN showed significantly higher expression in the metastatic cancer cells than in non-metastatic cancer cells, and they verified the result in cell lines and in vivo using proteomics analysis (LC-MS/MS) and IHC staining, respectively (36). This evidence concerns the gene PTGFRN and cancer.